Virax Biolabs Group Limited
20 North Audley Street
London, W1K 6LX
United Kingdom
VIA EDGAR
March 28, 2023
U.S. Securities & Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, NE
Attn: Lauren Hamill
|
|
|
| Re: | Virax Biolabs Group Limited |
|
| Registration Statement on Form F-1 |
|
| Filed March 22, 2023 |
|
| File No. 333-270734 |
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m., Eastern Time, on March 30, 2023, or as soon as thereafter practicable.
|
|
| Very truly yours, |
|
|
| /s/ James Foster |
| James Foster Chief Executive Officer |
|
|
|
DOCPROPERTY "DocID" \* MERGEFORMAT 23722827.1
240437-10005
